Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 76

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 76
---
 restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our
ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability
to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term
but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances
and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or
grant licenses on terms unfavorable to us.

Insiders will continue to have substantial influence over us after this offering, which could limit your ability to affect the outcome of key transactions, including a change of control.

After this offering, our directors,
officers, holders of more than 5% of our outstanding shares and their respective affiliates will beneficially own shares representing
approximately 64% of our outstanding Ordinary Shares, assuming no exercise of the Representative’s option to purchase additional
shares and additional warrants without giving effect to any shares that certain of these holders may make through our directed share program
or otherwise. As a result, these shareholders, if they act together, will be able to influence our management and affairs and all matters
requiring shareholder approval, including the election of directors and approval of significant corporate transactions. This concentration
of ownership may have the effect of delaying or preventing a change in control of our company and might affect the market price of our
Ordinary Shares.

The JOBS Act, allows us to postpone the date by which we must comply with some of the laws and regulations intended to protect investors and to reduce the amount of information we provide in our reports filed with the SEC, which could undermine investor confidence in our company and adversely affect the market price of our ADSs or our Ordinary Shares.

For so long as we remain
an “emerging growth company” as defined in the JOBS Act, we intend to take advantage of certain exemptions from various requirements
that are applicable to public companies that are not “emerging growth companies” including:

| ● | the provisions of the Sarbanes-Oxley                                                                                                    
 Act requiring that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal 
 control over financial reporting;                                                                                                       |

| ● | Section 107 of the JOBS                                                                                                       
 Act, which provides that an “emerging growth company” can take advantage of the extended transition period provided in        
 Section 7(a)(2